Morphine is one of the most commonly prescribed medications for the treatment of chronic pain after a spinal cord injury (SCI). Despite widespread use, however, little is known about the secondary consequences of morphine use after SCI. Unfortunately, our previous studies show that administration of a single dose of morphine, in the acute phase of a moderate spinal contusion injury, significantly attenuates locomotor function, reduces weight gain, and produces symptoms of paradoxical pain (Hook et al., 2009). The current study focused on the cellular mechanisms that mediate these effects. Based on data from other models, we hypothesized that pro-inflammatory cytokines might play a role in the morphineinduced attenuation of function. Experiment 1 confirmed that systemic morphine (20 mg/kg) administered one day after a contusion injury significantly increased expression levels of spinal IL-1b 24 h later.
a b s t r a c t
Morphine is one of the most commonly prescribed medications for the treatment of chronic pain after a spinal cord injury (SCI). Despite widespread use, however, little is known about the secondary consequences of morphine use after SCI. Unfortunately, our previous studies show that administration of a single dose of morphine, in the acute phase of a moderate spinal contusion injury, significantly attenuates locomotor function, reduces weight gain, and produces symptoms of paradoxical pain (Hook et al., 2009) . The current study focused on the cellular mechanisms that mediate these effects. Based on data from other models, we hypothesized that pro-inflammatory cytokines might play a role in the morphineinduced attenuation of function. Experiment 1 confirmed that systemic morphine (20 mg/kg) administered one day after a contusion injury significantly increased expression levels of spinal IL-1b 24 h later.
Experiment 2 extended these findings, demonstrating that a single dose of morphine (90 lg, i.t.) applied directly onto the spinal cord increased expression levels of spinal IL-1b at both 30 min and 24 h after administration. Experiment 3 showed that administration of an interleukin-1 receptor antagonist (IL1ra, i.t.) prior to intrathecal morphine (90 lg), blocked the adverse effects of morphine on locomotor recovery. Further, pre-treatment with 3 lg IL-1ra prevented the increased expression of at-level neuropathic pain symptoms that was observed 28 days later in the group treated with morphine-alone. However, the IL-1ra also had adverse effects that were independent of morphine. Treatment with the IL-1ra alone undermined recovery of locomotor function, potentiated weight loss and significantly increased tissue loss at the injury site. Overall, these data suggest that morphine disrupts a critical balance in concentrations of pro-inflammatory cytokines in the spinal cord, and this undermines recovery of function.
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Introduction
Our previous studies suggest that morphine, administered in the acute phase of a spinal contusion injury, significantly undermines recovery of function and increases the expression of paradoxical pain symptoms in the chronic phase of injury (Hook et al., 2007 (Hook et al., , 2009 ). Despite producing analgesia, a single dose of systemic morphine administered one day after a moderate contusion injury, led to allodynic responses to innocuous sensory stimuli (three weeks later), decreased sensory function, decreased weight gain, and increased lesion size when compared with vehicle-treated controls (Hook et al., 2007) . Intrathecal morphine significantly attenuated the recovery of locomotor function, decreased weight gain, increased the incidence of autophagia, and increased lesion size rostral to the injury site (Hook et al., 2009) . These data suggest that caution is warranted when administering morphine in the acute phase of a spinal cord injury (SCI). For SCI patients faced with a lifetime of intractable pain, however, simply removing morphine as a potential analgesic is not an option. It is essential that we further our understanding of the consequences of, and molecular mechanisms engaged by, commonly used opiate analgesics.
Recent studies have implicated the immune system in the development of the 'paradoxical' pain observed with morphine administration (Watkins et al., 2005 (Watkins et al., , 2007 Scholz and Woolf, 2007) . These studies have shown that repeated morphine administration activated microglia and astrocytes (Song and Zhao, 2001; Cui et al., 2006; Raghavendra et al., 2002; Tai et al., 2006) , and increased TNFa, IL-1b and IL-6 expression in the spinal cord (Johnston et al., 2004; Raghavendra et al., 2002; Tai et al., 2006) . These pro-inflammatory cytokines block the analgesic effects of opioids (Gul et al., 2000; Szabo et al., 2002) , and have been linked to the development of paradoxical pain symptoms. Indeed, at a cellular level, IL-1b has been shown to facilitate substance-P release from primary afferent neurons in the spinal dorsal horn (Inoue et al., 
